Study #2023-1062
Phase II trial of Ubamatamab alone or in combination with Cemiplimab in MUC16-Expressing SMARCB1-deficient malignancies
MD Anderson Study Status
Enrolling
Treatment Agent
Ubamatamab, Cemiplimab
Description
To find out if ubamatamab, given by itself or in combination with cemiplimab, can help to control the disease in participants with renal medullary carcinoma (RMC) and epithelioid sarcoma (ES).
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
SMARCB1-Deficient Malignancies
Study phase:
Phase II
Physician name:
Pavlos Msaouel
Department:
Genitourinary Medical Oncology
For general questions about clinical trials:
1-877-632-6789
Help #EndCancer
Give Now
Your gift will help make a tremendous difference.
Donate Blood
Our patients depend on blood and platelet donations.
Shop MD Anderson
Show your support for our mission through branded merchandise.